#ProQR had hoped to see NHP editing efficiencies for new AX-0810 #cholestatic disease candidate, but largely preclinical data with older (less potent candidate).

Guidance for CTA remains Q2 (though I am skeptical they can meet it) and topline data in Q4.
www.proqr.com/files/2025-0...

Honoured to to be part of this Future of Hepatology session at @easlnews.bsky.social #EASL2025, discussing the promise of #microbiome related therapies in #PSC #cholestatic liver disease - where have we come since the original #FMT #PSC pilot study by @DrAllegrettiIBD? doi.org/10.14309/ajg...